2023
DOI: 10.31083/j.jin2202042
|View full text |Cite
|
Sign up to set email alerts
|

A Nomogram Model for Predicting Prognosis in Spontaneous Intracerebral Hemorrhage Patients

Abstract: Intracranial hemorrhage is the second most common stroke subtype following ischemic stroke and usually induces high mortality and disability. Here, we conducted a retrospective study to establish a nomogram clinical prediction model. Methods: First, the baseline data of patients who presented to our hospital in 2015-2021 were collected and compared (789 patients for the training cohort and 378 patients for the validation cohort). Second, univariate and binary logistic analyses were performed to screen out alte… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 39 publications
0
1
0
Order By: Relevance
“…We and others think that a definitive main phase RCT could resolve these remaining uncertainties and be integrated into physicians’ clinical routine (Figure). 47,62,68–73 Funding agencies in the Global Cardiovascular Research Funders Forum Multinational Clinical Trials Initiative (https://www.bhf.org.uk/for-professionals/information-for-researchers/gcrff-multinational-clinical-trials-initiative) and the Australian NHMRC Medical Research Future Fund have provided funding for ASPIRING (Antiplatelet Secondary Prevention International Randomized Study After Intracerebral Hemorrhage), to follow its external pilot phase (Table 4). This event-driven RCT aims to recruit 4148 CH survivors (2074 per group) over 4 years (starting in mid-2024) to detect 947 MACE primary outcome events over ≥1 year of follow-up if the MACE event rate is 11.1% per year in the comparator group, 19,41,49,67 to detect an effect size of 0.81 from antiplatelet agents (aspirin or clopidogrel) 5,51 with a 2-sided alpha of 0.05 and 90% power.…”
Section: Implications For Future Researchmentioning
confidence: 99%
“…We and others think that a definitive main phase RCT could resolve these remaining uncertainties and be integrated into physicians’ clinical routine (Figure). 47,62,68–73 Funding agencies in the Global Cardiovascular Research Funders Forum Multinational Clinical Trials Initiative (https://www.bhf.org.uk/for-professionals/information-for-researchers/gcrff-multinational-clinical-trials-initiative) and the Australian NHMRC Medical Research Future Fund have provided funding for ASPIRING (Antiplatelet Secondary Prevention International Randomized Study After Intracerebral Hemorrhage), to follow its external pilot phase (Table 4). This event-driven RCT aims to recruit 4148 CH survivors (2074 per group) over 4 years (starting in mid-2024) to detect 947 MACE primary outcome events over ≥1 year of follow-up if the MACE event rate is 11.1% per year in the comparator group, 19,41,49,67 to detect an effect size of 0.81 from antiplatelet agents (aspirin or clopidogrel) 5,51 with a 2-sided alpha of 0.05 and 90% power.…”
Section: Implications For Future Researchmentioning
confidence: 99%